[en] Calmodulin (CaM) contributes to estrogen receptor a (ER)-mediated transcription. In order to study the underlying mechanisms, we synthesized a peptide including the CaM binding site: ERa17p (P295-T311). This peptide inhibited ER-CaM association, unlike two analogs in which two amino acids required for CaM binding were substituted. Exposure of MCF-7 cells to ERa17p down regulated ER, stimulated ER-dependent transcription and enhanced the proliferation of ER-positive breast cancer cell lines. Interestingly, ERa17p analogs unable to bind to CaM induced similar responses, demonstrating that ERa17p-mediated effects are mainly relevant to mechanisms independent of ER-CaM dissociation. The P295-T511 motif is indeed a platform for multiple post-translational modifications not necessarily CaM-dependent. The additional finding that deletion of the P295-T311 sequence in ER produced a constitutive transcriptional activity revealed that this platform motif has autorepressive functions. With regard to cell function, association of CaM to ER would counteract this autorepression, leading thereby to enhanced ER-mediated transactivation.
Disciplines :
Immunology & infectious disease Oncology
Author, co-author :
Gallo, Dominique
Jacquemotte, Françoise
Cleeren, Anny
Laïos, Ioanna
Hadiy, Samira
Rowlands, Martin G.
Caille, Olivier
Nonclercq, Denis ; Université de Mons > Faculté de Médecine et de Pharmacie > Service d'Histologie
Atherton E., and Sheppard R.C. Solid Phase Peptide Synthesis: A Practical Approach (1989), IRL Press, Oxford
Biswas D.K., Reddy P.V., Pickard M., Makkad B., Pettit N., and Pardee A.B. Calmodulin is essential for estrogen receptor interaction with its motif and activation of responsive promoter. J. Biol. Chem. 273 (1998) 33817-33824
Borras M., Lacroix M., Legros N., and Leclercq G. Estrogen receptor-negative/progesterone receptor-positive Evsa-T mammary tumor cells: a model for assessing the biological property of this peculiar phenotype of breast cancers. Cancer Lett. 120 (1997) 23-30
Bouhoute A., and Leclercq G. Modulation of estradiol and DNA binding to estrogen receptor upon association with calmodulin. Biochem. Biophys. Res. Commun. 208 (1995) 748-755
Brohee R., Nonclercq D., Journe D.N., Toubeau G., Falmagne P., Leclercq G., Heuson-Stiennon J.A., and Laurent G. Demonstration of estrogen receptors and of estrogen responsiveness in the HKT-1097 cell line derived from diethylstilbestrol-induced kidney tumors. In Vitro Cell. Dev. Biol. Anim. 36 (2000) 640-649
Castoria G., Migliaccio A., Nola E., and Auricchio F. In vitro interaction of estradiol receptor with Ca2+-calmodulin. Mol. Endocrinol. 2 (1988) 167-174
Cheskis B.J. Regulation of cell signalling cascades by steroid hormones. J. Cell. Biochem. 93 (2004) 20-27
Conway K., Parrish E., Edmiston S.N., Tolbert D., Tse C.K., Geradts J., Livasy C.A., Singh H., Newman B., and Millikan R.C. The estrogen receptor-alpha A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study. Breast Cancer Res. 7 (2005) R871-R880
de Longueville F., Lacroix M., Barbuto A.M., Bertholet V., Gallo D., Larsimont D., Marcq L., Zammatteo N., Boffe S., Leclercq G., and Remacle J. Molecular characterization of breast cancer cell lines by a low-density microarray. Int. J. Oncol. 27 (2005) 881-892
Evans R.M. The steroid and thyroid hormone receptor superfamily. Science 240 (1988) 889-895
Evinger III A.J., and Levin E.R. Requirements for estrogen receptor alpha membrane localization and function. Steroids 70 (2005) 361-363
Fuqua S.A., Wiltschke C., Zhang Q.X., Borg A., Castles C.G., Friedrichs W.E., Hopp T., Hilsenbeck S., Mohsin S., O'Connell P., and Allred D.C. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res. 60 (2000) 4026-4029
Garcia Pedrero J.M., Del Rio B., Martinez-Campa C., Muramatsu M., Lazo P.S., and Ramos S. Calmodulin is a selective modulator of estrogen receptors. Mol. Endocrinol. 16 (2002) 947-960
Green S., Walter P., Kumar V., Krust A., Bornert J.M., Argos P., and Chambon P. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 320 (1986) 134-139
Herynk M.H., and Fuqua S.A. Estrogen receptor mutations in human disease. Endocr. Rev. 25 (2004) 869-898
Iannone M.A., Simmons C.A., Kadwell S.H., Svoboda D.L., Vanderwall D.E., Deng S.J., Consler T.G., Shearin J., Gray J.G., and Pearce K.H. Correlation between in vitro peptide binding profiles and cellular activities for estrogen receptor-modulating compounds. Mol. Endocrinol. 18 (2004) 1064-1081
Imai Y., Matsushima Y., Sugimura T., and Terada M. A simple and rapid method for generating a deletion by PCR. Nucleic Acids Res. 19 (1991) 2785
Jacquot Y., Gallo D., and Leclercq G. Estrogen receptor alpha-Identification by a modeling approach of a potential polyproline II recognizing domain within the AF2 region of the receptor that would play a role of prime importance in its mechanism of action. J. Steroid Biochem. Mol. Biol. 104 (2007) 1-10
Journe F., Chaboteaux C., Dumon J.C., Leclercq G., Laurent G., and Body J.J. Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells. Br. J. Cancer 91 9 (2004) 1703-1710
Kaiser E., Colescott R.L., Bossinger C.D., and Cook P.I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 34 (1970) 595-598
Kampa M., and Castanas E. Membrane steroid receptor signaling in normal and neoplastic cells. Mol. Cell. Endocrinol. 246 (2006) 76-82
Kincaid R.L., Vaughan M., Osborne Jr. J.C., and Tkachuk V.A. Ca2+-dependent interaction of 5-dimethylaminonaphthalene-1-sulfonyl-calmodulin with cyclic nucleotide phosphodiesterase, calcineurin, and troponin I. J. Biol. Chem. 257 (1982) 10638-10643
Knorr R., Trzeciak A., Bannwarth W., and Gillessen D. New coupling reagents in peptide chemistry. Tetrahedron Lett. 30 (1989) 1927-1930
Kong E.H., Heldring N., Gustafsson J.A., Treuter E., Hubbard R.E., and Pike A.C. Delineation of a unique protein-protein interaction site on the surface of the estrogen receptor. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 3593-3598
Lacroix M., and Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res. Treat. 83 (2004) 249-289
Laios I., Journe F., Nonclercq D., Vidal D.S., Toillon R.A., Laurent G., and Leclercq G. Role of the proteasome in the regulation of estrogen receptor alpha turnover and function in MCF-7 breast carcinoma cells. J. Steroid. Biochem. Mol. Biol. 94 (2005) 347-359
Leclercq G., Lacroix M., Laios I., and Laurent G. Estrogen receptor alpha: impact of ligands on intracellular shuttling and turnover rate in breast cancer cells. Curr. Cancer Drug Targets 6 (2006) 39-64
Lee H., and Bai W. Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Mol. Cell. Biol. 22 (2002) 5835-5845
Li L., Li Z., and Sacks D.B. Calmodulin regulates the transcriptional activity of estrogen receptors. Selective inhibition of calmodulin function in subcellular compartments. J. Biol. Chem. 278 (2003) 1195-1200
Li L., Li Z., and Sacks D.B. The transcriptional activity of estrogen receptor-alpha is dependent on Ca2+/calmodulin. J. Biol. Chem. 280 (2005) 13097-13104
Li L., Li Z., Howley P.M., and Sacks D.B. E6AP and calmodulin reciprocally regulate estrogen receptor stability. J. Biol. Chem. 281 (2006) 1978-1985
Li Z., Joyal J.L., and Sacks D.B. Calmodulin enhances the stability of the estrogen receptor. J. Biol. Chem. 276 (2001) 17354-17360
McCague R., Rowlands M.G., Grimshaw R., and Jarman M. Evidence that tamoxifen binds to calmodulin in a conformation different to that when binding to estrogen receptors, through structure-activity study on ring-fused analogues. Biochem. Pharmacol. 48 (1994) 1355-1361
Metivier R., Penot G., Hubner M.R., Reid G., Brand H., Kos M., and Gannon F. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115 (2003) 751-763
Nawaz Z., and O'Malley B.W. Urban renewal in the nucleus: is protein turnover by proteasomes absolutely required for nuclear receptor-regulated transcription?. Mol. Endocrinol. 18 (2004) 493-499
Picard D., Kumar V., Chambon P., and Yamamoto K.R. Signal transduction by steroid hormones: nuclear localization is differentially regulated in estrogen and glucocorticoid receptors. Cell Regul. 1 (1990) 291-299
Pons M., Gagne D., Nicolas J.C., and Mehtali M. A new cellular model of response to estrogens: a bioluminescent test to characterize (anti) estrogen molecules. Biotechniques 9 (1990) 450-459
Reid G., Hubner M.R., Metivier R., Brand H., Denger S., Manu D., Beaudouin J., Ellenberg J., and Gannon F. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol. Cell. 11 (2003) 695-707
Rodriguez A.L., Tamrazi A., Collins M.L., and Katzenellenbogen J.A. Design, synthesis, and in vitro biological evaluation of small molecule inhibitors of estrogen receptor alpha coactivator binding. J. Med. Chem. 47 (2004) 600-611
Rossini G.P. The quaternary structures of untransformed steroid hormone receptors: an open issue. J. Theor. Biol. 166 (1994) 339-353
Rowlands M.G., Parr I.B., McCague R., Jarman M., and Goddard P.M. Variation of the inhibition of calmodulin dependent cyclic AMP phosphodiesterase amongst analogues of tamoxifen; correlations with cytotoxicity. Biochem. Pharmacol. 40 (1990) 283-289
Scatchard G. The attraction of proteins for small molecules and ions. Ann. N.Y. Acad. Sci. 51 (1949) 660-672
Seielstad D.A., Carlson K.E., Kushner P.J., Greene G.L., and Katzenellenbogen J.A. Analysis of the structural core of the human estrogen receptor ligand binding domain by selective proteolysis/mass spectrometric analysis. Biochemistry 34 (1995) 12605-12615
Sentis S., Le Romancer M., Bianchin C., Rostan M.C., and Corbo L. SUMOylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Mol. Endocrinol. 19 (2005) 2671-2684
Seo H.S., Larsimont D., Ma Y., Laios I., and Leclercq G. Regulation of estrogen receptor levels by ligand-induced release of compound(s) in MCF-7 cells. Mol. Cell. Endocrinol. 164 (2000) 19-29
Seo H.S., DeNardo D.G., Jacquot Y., Laios I., Vidal D.S., Zambrana C.R., Leclercq G., and Brown P.H. Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha. Breast Cancer Res. Treat. 99 (2006) 121-134
Shang Y., Hu X., DiRenzo J., Lazar M.A., and Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103 (2000) 843-852
Shao D., Berrodin T.J., Manas E., Hauze D., Powers R., Bapat A., Gonder D., Winneker R.C., and Frail D.E. Identification of novel estrogen receptor alpha antagonists. J. Steroid. Biochem. Mol. Biol. 88 (2004) 351-360
Singer A.L., Sherwin R.P., Dunn A.S., and Appleman M.M. Cyclic nucleotide phosphodiesterases in neoplastic and nonneoplastic human mammary tissues. Cancer Res. 36 (1976) 60-66
Singh R.R., and Kumar R. Steroid hormone receptor signaling in tumorigenesis. J. Cell. Biochem. 96 (2005) 490-505
Strobl J.S., Peterson V.A., and Woodfork K.A. A survey of human breast cancer sensitivity to growth inhibition by calmodulin antagonists in tissue culture. Biochem. Pharmacol. 47 (1994) 2157-2161
Wang C., Fu M., Angeletti R.H., Siconolfi-Baez L., Reutens A.T., Albanese C., Lisanti M.P., Katzenellenbogen B.S., Kato S., Hopp T., Fuqua S.A., Lopez G.N., Kushner P.J., and Pestell R.G. Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. J. Biol. Chem. 276 (2001) 18375-18383
Wang R.A., Mazumdar A., Vadlamudi R.K., and Kumar R. P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. Embo J. 21 (2002) 5437-5447
Warnmark A., Treuter E., Gustafsson J.A., Hubbard R.E., Brzozowski A.M., and Pike A.C. Interaction of transcriptional intermediary factor 2 nuclear receptor box peptides with the coactivator binding site of estrogen receptor alpha. J. Biol. Chem. 277 (2002) 21862-21868
Wei J.W., Hickie R.A., and Klaassen D.J. Inhibition of human breast cancer colony formation by anticalmodulin agents: trifluoperazine, W-7, and W-13. Cancer Chemother. Pharmacol. 11 (1983) 86-90
Xu H.E., Stanley T.B., Montana V.G., Lambert M.H., Shearer B.G., Cobb J.E., McKee D.D., Galardi C.M., Plunket K.D., Nolte R.T., Parks D.J., Moore J.T., Kliewer S.A., Willson T.M., and Stimmel J.B. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature 415 (2002) 813-817
Yan F., Gao X., Lonard D.M., and Nawaz Z. Specific ubiquitin-conjugating enzymes promote degradation of specific nuclear receptor coactivators. Mol. Endocrinol. 17 (2003) 1315-1331
Ylikomi T., Bocquel M.T., Berry M., Gronemeyer H., and Chambon P. Cooperation of proto-signals for nuclear accumulation of estrogen and progesterone receptors. Embo J. 11 (1992) 3681-3694
